One of our clients, the Belarus Republican Scientific and Technical Library recently posted an article on how they support innovation. They open with the statement that “The novelty, effectiveness and…
Here’s a copy of the recent talk on Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition. It’s based on the book Make Better Decisions, which distills insights…
DrugPatentWatch was used in a recent research study on branded drug sales following generic entry. In this paper, authors Jeffrey Fujimoto, Daniel M Tien, Sophie Snyder, Jeppe A Hertz, and…
DrugPatentWatch serves companies across the drug development-delivery sector. A common request among drug manufacturers, payers, and suppliers alike is anticipation of which branded drugs will face generic competition, and when…
Changes in drug markets can create growth opportunities for API manufacturers and CDMOs alike. Whether change comes from generic entry, from new formulations of drugs, or from competition from novel…
DrugPatentWatch has deep resources to support patent prosecution and patent litigation, but it is also used by law firms for business development. Find weak claims One of the first tweaks…
The launch of a new product can be a daunting task. The main reason this happens is that no matter how many times your company has managed to enter new…
This article was originally published by Garth Boehm, Lixin Yao, Liang Hana, and Qiang Zheng in Acta Pharmaceutica Sinica under a creative commons license. Abstract The key events in the…
DrugPatentWatch can help identify generic entrants at the earliest stages Many clients come to DrugPatentWatch seeking to identify generic entrants well before they launch. CDMOs, equipment manufacturers, regulatory consultants, and…
The latest Swiss Biotech annual report focuses on the theme of shaping change. Change is a theme DrugPatentWatch is very familiar with — whether it is a matter of tracking…
